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Sympathetic activation during acute myocardial infarction (MI) is an important arrhythmo-
genic mechanism, but the role of central autonomic inputs and their modulating factors
remain unclear. Using the in vivo rat-model, we examined the effects of clonidine, a cen-
trally acting sympatholytic agent, in the presence or absence of myocardial endothelin-B
(ETB) receptors. We studied wild-type (n=20) and ETB-deficient rats (n=20) after perma-
nent coronary ligation, with or without pretreatment with clonidine. Cardiac rhythm was
continuously recorded for 24 h by implantable telemetry devices, coupled by the assess-
ment of autonomic and heart failure indices. Sympathetic activation and arrhythmogenesis
were more prominent in ETB-deficient rats during the early phase post-ligation. Clonidine
improved these outcomes throughout the observation period in ETB-deficient rats, but
only during the delayed phase in wild-type rats. However, this benefit was counterbal-
anced by atrioventricular conduction abnormalities and by higher incidence of heart failure,
the latter particularly evident in ETB-deficient rats. Myocardial ETB-receptors attenuate the
arrhythmogenic effects of central sympathetic activation during acute MI. ETB-receptor
deficiency potentiates the sympatholytic effects of clonidine and aggravates heart fail-
ure. The interaction between endothelin and sympathetic responses during myocardial
ischemia/infarction and its impact on arrhythmogenesis and left ventricular dysfunction
merits further investigation.
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INTRODUCTION
Sudden cardiac death (SCD) accounts for 13% of total mor-
tality from natural causes in the general population and has
emerged as an important health-related problem. In most cases,
SCD is caused by ventricular tachyarrhythmias, i.e., ventricu-
lar tachycardia (VT) and ventricular fibrillation (VF), triggered
by acute myocardial infarction (MI) (1). Driven by its high-
societal impact, in-depth understanding of the pathophysiology
of ischemia-induced VT/VF has attracted multifaceted research
efforts, with a view toward decreasing SCD rates.
The role of sympathetic activation in the pathogenesis of VT/VF
during acute MI has been known for decades (2); myocardial
ischemia leads to local norepinephrine release from sympathetic
nerve terminals, primarily via non-exocytotic mechanisms, fol-
lowing an immediate exocytotic phase (3). The elicited positive
inotropic response serves the maintenance of cardiac output,
but local catecholamine surge alters ventricular electrophysiolog-
ical properties and creates an arrhythmogenic milieu (4). These
mechanisms may predominate during the early period post-MI,
corresponding clinically to the critical pre-hospital stage, during
which VT/VF carries a dismal prognosis (1).
Recently, accumulated evidence indicates endothelin-1 (ET-1),
a ubiquitous 21-aminoacid peptide, as an important moderator
of sympathetic activation (5) and arrhythmogenesis (6) during
acute-MI. Both (ETA and ETB) ET-receptors, located in sympa-
thetic nerve varicosities in the ventricular myocardium (7), exert
significant, albeit opposing effects; ETA-receptors inhibit norep-
inephrine re-uptake, whereas ETB-receptors attenuate exocytotic
norepinephrine release (8). These actions gain pathophysiolog-
ical significance in the MI-setting, during which ETA-receptor
stimulation enhances norepinephrine release, but the role of ETB-
receptors remains unclear (9). Experimental studies have shown
increased sympathetic activation and arrhythmogenesis in the
absence of functional ETB-receptors in the ischemic ventricular
myocardium (7, 10); however, most data originate from ex vivo,
isolated (hence, denervated) beating hearts, thereby hindering the
deduction of firm conclusions on the role of ETB-receptors, in the
presence of intact autonomic innervation (11).
In addition to myocardial norepinephrine release from intrin-
sic nerve terminals, central sympathetic activation occurs after
ischemia, mediated by locally produced metabolites that stimulate
afferent myocardial nerve fibers; in turn, efferent autonomic dis-
charges from the brain stem modulate left ventricular (LV) func-
tion and electrophysiology (12). Earlier studies in anesthetized
dogs demonstrated increased cardiac sympathetic nerve activity
during MI that was prevented by clonidine, a centrally acting
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α2-adrenergic-receptor agonist (13). Efferent inputs to the heart
are arrhythmogenic, as shown by continuous recordings of the
left stellate ganglion in conscious dogs, revealing the precedence
of VT/VF by enhanced sympathetic nerve activity (14), and by
effective clinical management of intractable VT/VF by surgical or
thoracoscopic denervation (15). Despite this knowledge, the rela-
tive impact of central sympathetic activation on VT/VF along with
the course of acute-MI, and the potential modulating effects of
ETB-receptors in the ventricular myocardium are not well defined.
Here, we examined arrhythmogenesis, as well as indices of
sympathetic activation and LV failure, in the in vivo acute-MI
rat-model; we compared these outcomes in groups with or with-
out pretreatment with clonidine, in the presence or absence of
myocardial ETB-receptors.
MATERIALS AND METHODS
ANIMAL STUDY POPULATION AND ETHICS
The animal study population consisted of 40 rats, 20–24 weeks of
age, weighing 225–300 g. The animals were housed in plexiglas-
cages in groups of two, with free access to standard rodent pellet-
diet and water. The laboratory conditions were kept optimal, in
terms of temperature (20–22°C), humidity (~70%), and light/dark
cycles (12/12 h). The study protocol adheres to the guiding prin-
ciples of the declaration of Helsinki (on animal research) and
to European legislation (European Union directive for the protec-
tion of animals used for scientific purposes 609/1986, revised in
2010/63/EU); all procedures were approved by the institutional
ethics’ committee and by the regulatory state authorities.
The role of ETB-receptors in the ventricular myocardium was
examined by a “subtraction model,” using a previously character-
ized (16) Wistar–Imamichi rat strain (n= 20), kindly provided by
Professor M. Yanagisawa (Southwestern Medical Center, Dallas,
TX, USA and University of Tsukuba, Tsukuba, Japan). These ani-
mals carry a (naturally occurring) deletion in the gene encoding
for the ETB-receptor and die prematurely of intestinal obstruction.
This phenotype is rescued by directed ETB transgene-expression,
leading to normal development of enteric nervous system and
brain function, and provides a valuable tool in the study of
ETB-receptors in the cardiovascular system (17).
STUDY PROTOCOL
Cardiac rhythm was recorded continuously for 24 h post-MI, with
the use of miniature electrocardiography (ECG) telemetry trans-
mitters; these devices permit long-term assessment in conscious
animals, without the confounding effects of anesthesia (18). The
survival duration was accurately determined from the stored ECG-
recordings; mortality was further classified as tachyarrhythmic
(i.e., ventricular asystole, immediately preceded by VT/VF) or
bradyarrhythmic [i.e., gradual increase in sinus heart rate (HR),
followed by an abrupt onset of complete atrioventricular block and
asystole], the latter indicative of death due to heart failure (18, 19).
TRANSMITTER IMPLANTATION
The telemetry transmitters (Dataquest, Data Sciences Interna-
tional, DSI, Transoma Medical, Arden Hills, MN, USA) were
implanted in the abdominal cavity, as described previously (20);
both leads were tunneled under the skin and secured at the right
axillary and left inguinal areas, respectively. The animals were
housed in individual cages, placed on a receiver that continuously
captured the ECG-signal, processed by a software program (A.R.T.
2.2, DSI ).
CLONIDINE ADMINISTRATION
Central sympathetic activation was examined with the use of
clonidine, a commonly applied pharmacological model; after an
initial peripheral α1-stimulation, the central action of clonidine
prevails, resulting in inhibition of sympathetic preganglionic neu-
rons and decreased sympathetic drive (21). As previously (22),
clonidine was given intraperitoneally (0.5 mg/kg), 1 h prior to the
experiments.
INDUCTION OF MYOCARDIAL INFARCTION
After tracheal intubation, the rats were mechanically ventilated
(rodent apparatus model 7025, Ugo Basile, Comerio, Italy), and
anesthesia was maintained with a mixture of oxygen and 2.5%
sevoflurane. MI was generated by permanent ligation at the mid-
dle segment of the left coronary artery, guided by the anatomic
landmarks provided by the pulmonary cone, the left atrium, and
the ventricular apex (23). MI was validated by inspection of a
pale, akinetic area, and by ST-segment elevation in a six-lead ECG
(QRS-Card digital PC-ECG, Pulse Biomedical Inc., PBI, Norris-
town, PA, USA, amplified by Cardiology Suite, version 4.05, PBI ).
The incision was closed in three layers and pneumothorax was
evacuated. Spontaneous respiration and consciousness resumed
within ~2 min after discontinuation of anesthesia.
ARRHYTHMIA ANALYSIS
The analysis of ECG-recordings adhered to the guidelines provided
by the (recently updated) Lambeth conventions for determination
of experimental arrhythmias (24). The tracings were manually
scrolled and the number of tachy- and bradyarrhythmic events
were recorded; the count of premature ventricular contractions,
couplets, or triplets was omitted, based on their uncertain sig-
nificance. As distinction between VT (four or more consecutive
premature ventricular contractions) and VF (indistinguishable
QRS deflections) may be occasionally difficult (19, 20), we report
them collectively as VT/VF; the duration of each episode was mea-
sured, aided by the time-scale provided by the software. Similarly,
we recorded transient atrioventricular conduction abnormalities,
not associated with bradyarrhythmic death. To account for differ-
ences in mortality, VT/VF duration during the entire observation
period was normalized for survival (18).
ARRHYTHMIA TIME-INTERVALS
The incidence of VT/VF is reported separately for phase I (i.e.,
during the first hour post-ligation, corresponding to ischemia and
the onset of myocardial necrosis), and phase II (i.e., from the
2nd until the 24th hour post-ligation, corresponding to evolving
MI, until the completion of necrosis). Such separation presents
the inherent limitation of producing temporal dissimilarities in
the characteristics within an animal-population in cases of exces-
sive early-phase mortality, but it is useful for its translational
value in the clinical setting, and also provides information on the
underlying arrhythmogenic mechanisms (25, 26).
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ECG-INDICES OF SYMPATHETIC ACTIVATION
Mean values of HR, calculated from sinus beats, are given sep-
arately for phases I and II. Furthermore, heart rate variability
(HRV), derived by fast Fourier transformation, is reported as the
ratio of low-frequency (LF, 0.195–0.605 Hz) to high-frequency
(HF, 0.605–2.5 Hz) bands (27). This index correlates with cate-
cholamine measurements (28), and permits the continuous assess-
ment of autonomic balance in conscious animals (29). For HRV-
analysis, we used the Kubios HRV-software (version 2.1, Biosignal
Analysis and Medical Imaging Group, Department of Applied
Physics, University of Eastern Finland, Kuopio, Finland) (30).
ACTIVITY MEASUREMENT
Acute LV failure was assessed by voluntary motor activity, recorded
by the analysis program (A.R.T. 2.2, DSI ). The software records
strength-variations in the telemetry-signal, in relation to the loca-
tion of the animal; changes in signal-amplitude are depicted as
counts, the number of which depends on total animal activity.
This variable correlates with the functional status, and has been
used as a surrogate marker for heart failure (27, 31, 32).
STATISTICAL ANALYSIS
Values are presented as mean± SEM. Kaplan–Meier survival
curves were constructed and differences in mortality were assessed
with Gehan’s Wilcoxon test. Categorical variables were compared
with Fisher’s exact (two-tailed) test. Continuous variables were
compared with analysis of variance, whereas their changes over
time were compared with analysis of variance for repeated mea-
sures, both followed by post hoc Newman–Keuls multi-stage test.
Statistical significance was defined at an alpha level of 0.05.
RESULTS
MORTALITY
As seen in Kaplan–Meier survival curves (Figure 1), mortality
was higher (p= 0.028) in ETB-deficient than in wild-type rats.
Clonidine had no overall effect, but a shift in the mode of death
was observed, from tachyarrhythmic (83% of mortality in ETB-
deficient and 33% in wild-type rats) to bradyarrhythmic (100%
of mortality in both groups); this difference reached statistical
significance (p= 0.0152) in ETB-deficient rats.
SYMPATHETIC ACTIVATION
During phase I, HR and LF/HF ratio were higher in ETB-deficient
than in wild-type rats (Figure 2). Compared to the respective
untreated groups, both variables were lower after clonidine at
baseline and during phase I, without differences between groups.
During phase II, HR and LF/HF ratio were lower in ETB-deficient
than in wild-type rats. After clonidine, LF/HF ratio was similar,
although HR tended to be higher (p= 0.064) in ETB-deficient
rats.
VENTRICULAR ARRHYTHMIAS AND A–V BLOCK
During phase I, the number of VT/VF episodes was compara-
ble in the two groups, but their mean duration was longer in
ETB-deficient rats, resulting in longer (p= 0.00013) total VT/VF
duration. Compared to the respective untreated group, VT/VF
duration did not change significantly in clonidine-treated wild-
type rats, although variable responses were observed. In contrast,
FIGURE 1 | Kaplan–Meier survival curves. Total mortality was higher in
ETB-deficient (asterisk), than in wild-type rats.
FIGURE 2 | Sympathetic activation. Heart rate (upper panel) and low (LF)
to high (HF) frequency ratio (lower panel) were higher in ETB-deficient rats
during phase I (asterisks). Note their marked decrease after clonidine.
VT/VF duration decreased in ETB-deficient rats (p= 0.000159)
after clonidine, resulting from (marginally) fewer (p= 0.053) and
(mainly) shorter (p= 0.000641) episodes (Figure 3). Of note,
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FIGURE 3 |Ventricular arrhythmogenesis. Number and mean duration of
ventricular tachycardia (VT) and fibrillation (VF) episodes (upper panel). Note,
the decreased total duration (lower panel) in clonidine-treated ETB-deficient
rats during phase I, and in clonidine-treated wild-type rats during phase II.
transient second degree atrioventricular block was seen after cloni-
dine in both groups, namely, 1.0± 1.0 (of 8.7± 8.7 s duration) and
3.7± 2.4 (18.5± 13.5 s) episodes in ETB-deficient and wild-type
rats, respectively; these differences (between groups) did not reach
statistical significance.
Compared to wild-type rats, less (p= 0.0031) VT/VF episodes
occurred in ETB-deficient rats during phase II, resulting in
shorter (p= 0.0010) total duration. After clonidine pretreat-
ment, VT/VF duration was comparable in the two groups, due
to decreased values (p= 0.0014) in wild-type rats. As in phase
I, a mean of 0.7± 0.4 (of 1.8± 1.1 s duration) and 2.4± 1.3
episodes (10.5± 9.0 s) of second degree atrioventricular block
were seen in ETB-deficient and wild-type rats, respectively;
again, these differences (between groups) did not reach statistical
significance.
FIGURE 4 | Examples of tachy- and bradyarrhythmias. Examples of
ventricular arrhythmias (continuous strips) from an untreated (upper panel)
and a clonidine-treated (middle panel) ETB-deficient rat. Frequent episodes
of transient atrioventricular conduction abnormalities in a clonidine-treated
wild-type rat (lower panel). Numbers indicate duration in seconds.
When normalized for survival, total VT/VF duration (during
both phases) was markedly higher in untreated ETB-deficient rats
(414.6± 162.8 s), compared to the remaining three groups [i.e.,
untreated wild-type rats (26.1± 18.9 s, p= 0.0020), clonidine-
treated ETB-deficient rats (6.3± 2.7 s, p= 0.0063) and clonidine-
treated wild-type rats (7.8± 2.5 s, p= 0.0035)]. Representative
examples of VT/VF and atrioventricular block are shown in
Figure 4.
ACTIVITY
Activity-counts were lower in ETB-deficient (1307± 472) than in
wild-type rats (2296± 524) during the entire observation period
post-MI, albeit of marginal statistical significance (p= 0.088,
Figure 5). Clonidine did not change activity-counts in ETB-
deficient rats during phase I, but decreased them (p= 0.036) in
wild-type rats. Compared to the respective untreated groups, lower
values were found after clonidine in both groups during phase II,
but differences reached statistical significance (p= 0.0054) only in
ETB-deficient rats.
DISCUSSION
Sympathetic activation is an essential mechanism responsible for
arrhythmogenesis during acute-MI, but the contribution of cen-
tral autonomic inputs relative to local norepinephrine release
remains under investigation. We examined the effects of (the
centrally acting sympatholytic agent) clonidine on rhythm distur-
bances in the in vivo MI-rat-model, focusing on the modulating
actions of myocardial ETB-receptors.
BRADYCARDIC EFFECTS OF CLONIDINE
Clonidine-pretreatment decreased HR and deteriorated atrioven-
tricular conduction in both rat-groups throughout the observa-
tion period. Our findings are similar to those seen after intrathecal
clonidine (from the spinal cord) in a canine-model of ischemia
(superimposed on healed-MI and heart failure); this study (33)
reported 32% reduction in HR, 22% increase in PQ interval,
and 122% increase in Wenckebach cycle-length. The bradycardic
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FIGURE 5 | Activity-counts. Compared to the respective untreated groups,
activity-counts were lower in clonidine-treated wild-type rats during phase I
and in clonidine-treated ETB-deficient rats during phase II (asterisks).
effects of clonidine on the sinus and atrioventricular nodes are
thought to be secondary to autonomic modulation, rather than a
direct effect on cardiac tissues (33).
CENTRAL SYMPATHETIC ACTIVATION AND ARRHYTHMOGENESIS IN
WILD-TYPE RATS
The effects of clonidine in wild-type rats differed between the
two (post-ligation) phases. Phase I was characterized by variable
responses, but clonidine had no overall effect on VT/VF dura-
tion at this stage. Thus, the involvement of central sympathetic
activation on early-phase arrhythmogenesis post-MI seems to be
minor. Conversely, clonidine-pretreatment decreased (by ~50%)
the number and total duration of VT/VF episodes during phase II.
Using neurographic recordings from postganglionic cardiac
efferent nerves in conscious dogs, Zhou et al. (14) found
augmented nerve activity immediately preceding most VT/VF
episodes, underscoring its role in triggering arrhythmic events.
Additional arrhythmogenic action appears to be exerted via
enhanced dispersion of refractoriness, demonstrated by ventric-
ular electrograms following left stellate ganglion stimulation in
anesthetized dogs, although marked variation in the individual
responses was present (34, 35). Further corroborating these obser-
vations, attenuated cardiac sympathetic activity and VT/VF were
reported in dogs [in the aforementioned study by Issa et al. (33)]
after intrathecal clonidine. Nonetheless, the temporal pattern of
arrhythmogenesis, caused by central sympathetic inputs, along
with the course of acute-MI cannot be defined from these studies
(14, 33–35).
In a single experiment in the ovine model, Jardine et al. (36)
reported increased nerve activity 30 min after coronary occlusion,
leading toVF. This topic was subsequently systematically addressed
by the same researchers (37) in a group of 11 sheep; enhanced car-
diac sympathetic nerve frequency was evident (a mean of) 1 h
after coronary occlusion, but again, variable degree of activation
was noted (37). Examined together, the findings of the present
work in the context of previous studies (14, 33–37), indicate that
(in the presence of ETB-receptors in the ventricular myocardium)
cardiac sympathetic nerve activity participates only to a minor
extent in the mechanisms underlying early-phase VT/VF, although
variable responses occur; in contrast, central sympathetic activa-
tion contributes to delayed-phase arrhythmogenesis. In addition
to autonomic responses, this temporal pattern can be attributed
to differences in the substrate, created by ischemia versus evolving
MI (1, 25). Furthermore, LV-afterload reduction [often observed
as a delayed effect after clonidine administration (38)] may have
contributed to this pattern, by decreasing wall-stress and, thereby,
stretch-induced VT/VF (39).
The contribution of central sympathetic activation to delayed-
phase arrhythmogenesis, indicated by our results, may appear
contradictory to previous experiments in Langendorff-perfused
rat-hearts, in which catecholamines failed to restore phase II
VT/VF (40); further pointing toward this direction, relatively lim-
ited contribution of the adrenal medulla on arrhythmogenesis
was recently shown in the adrenalectomized in vivo rat-MI-model
(41). However, it should be pointed out that neurally released
and circulating norepinephrine activate adrenergic-receptors at
different myocardial areas, thereby producing dissimilar electro-
physiologic milieu and arrhythmogenic actions (42). We feel that
this important point needs further investigation in future studies.
CENTRAL SYMPATHETIC ACTIVATION AND ARRHYTHMOGENESIS IN
ETB-DEFICIENT RATS
Compared to wild-type rats, the course of sympathetic activ-
ity and arrhythmogenesis differed in our ETB-deficient group,
strongly suggesting modulating effects of ETB-receptors. As in
previous work from our laboratory (28, 41), we found higher
incidence of VT/VF in ETB-deficient rats during phase I, along
with a corresponding increase in mortality. This outcome concurs
also with observations in pharmacological studies, in which dual-
(ETA and ETB)-blockade (43) mitigated the protective effects of
ETA-receptor-blockade during this time-frame (44). Thus, func-
tioning myocardial ETB-receptors ameliorate arrhythmogenesis
during the early post-MI phase; decreased norepinephrine over-
flow, mediated by attenuated exocytotic release at this stage, has
been proposed as a likely explanation (45).
Contrasting phase I, phase II was characterized by lower
arrhythmogenesis in untreated ETB-deficient rats, in accordance
with previous results (28). The explanation for this finding is diffi-
cult, but catecholamine-depletion, secondary to excessive sympa-
thetic activation during phase I, has been put forward as a possible
mechanism (41).
In the present work, we found lower incidence of VT/VF in
clonidine-treated ETB-deficient rats during phase I; this resulted
mainly from shorter mean episode duration, in line with the well-
described sympathetic effects on the maintenance of VT/VF over
the ischemic-border (34). Thus, in contrast to wild-type rats, cen-
tral sympathetic inputs appear to exert an important role on
early-phase arrhythmogenesis in ETB-deficient rats. This obser-
vation can be hardly explained solely by the absence of protective
effects exerted by myocardial ETB-receptors, raising the possibil-
ity of enhanced central sympathetic activation in this rat strain.
This notion is reinforced by cellular studies in the brain of these
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rats, demonstrating elevated endothelin-converting-enzyme and
extracellular ET-1 levels at basal conditions (46).
The ET-system is known to be abundantly present in the central
nervous system (47), where it regulates several processes, includ-
ing brain stem function (48); thus, enhanced central sympathetic
activation may have contributed to arrhythmogenesis in our ETB-
deficient group. This hypothesis is supported by higher HR and
LF/HF ratio, observed in untreated ETB-deficient animals dur-
ing phase I, as these indices reflect the autonomic balance on the
sinus node, irrespective of myocardial catecholamine concentra-
tions. Further studies are needed on this intriguing topic, focusing
on the complex interaction between ET-1 and central sympathetic
activation.
LV DYSFUNCTION AND ETB-RECEPTORS
We observed a trend toward lower activity-counts (used as a sur-
rogate marker of acute LV failure) in untreated ETB-deficient rats,
when compared to untreated wild-type rats. The higher incidence
of heart failure, implied by our findings, is in agreement with
experiments in Langendorff-perfused rat-hearts in the setting of
global (10) or regional (49) ischemia, demonstrating prominent
LV dysfunction, caused by genetic deficiency or pharmacologi-
cal blockade of myocardial ETB-receptors. The (likely) increased
incidence of acute LV failure after clonidine in our experiments
(offsetting the reduction in arrhythmogenesis) adds important
information on this issue; although evident in both rat-groups,
this effect was more pronounced in ETB-deficient rats, as sug-
gested by a shift toward bradyarrhythmic mortality, by markedly
decreased activity-counts, and by higher HR during phase II.
The pathophysiologic link between ETB-receptors and LV dys-
function (in the setting of myocardial ischemia) is poorly under-
stood, although increased metabolic demand caused by excessive
sympathetic activation has been proposed (10). Nonetheless, the
(likely) higher incidence of heart failure after central sympa-
tholytic action (in our in vivo experiments) point toward addi-
tional mechanisms that may be operative. Pharmacological inter-
action between clonidine and cardiovascular ETB-receptors is also
possible, based on previous reports in rats (38), demonstrating
augmented sympatholytic effects of clonidine after ETB-receptor-
blockade (and the reverse after ETB-receptor-stimulation). This
topic requires thorough investigation in future work, using more
specific assessment of LV function and heart failure, including
methods of highlighting potential underlying mechanisms.
STRENGTHS AND LIMITATIONS
The topic examined in the present work is of high clinical signifi-
cance, fueled by accumulated evidence linking central sympathetic
activation with acute-MI and SCD (50). We investigated the mod-
ulating effects of ET-1 on this process, driven by experimental
data (7–10) and by clinical findings, demonstrating a twofold
increase in plasma ET-1 levels in patients with acute coronary
syndromes triggered by emotional stress (51). Focusing on the
role of ETB-receptors, we used a “subtraction” rat-model that
circumvents certain caveats associated with pharmacological ET-
receptor-blockade (8, 45). Lastly, our data, derived from conscious
animals, were not confounded by the effects of anesthesia on sym-
pathetic activation or arrhythmogenesis. Despite these merits, four
limitations should be acknowledged: first, implantable transmit-
ters, utilized in our experiments, enable thorough evaluation in
conscious animals, but HRV-indices reflect the net autonomic bal-
ance on the sinus node and cannot assess sympathetic and vagal
discharges separately. Second, we assessed the incidence of heart
failure based on bradyarrhythmic death rates, HR, and activity-
counts. However, (particularly the latter two of) these end-points
are non-specific and should be viewed only as suggestive of acute
heart failure, as they may have been confounded by known actions
of clonidine, despite the fact that these were likely exerted equally
to both animal-groups. Specifically, increased HR may have ensued
from reflex tachycardia secondary to hypotension, and low activity
counts may be attributed to the sedative effects of clonidine (52).
Thus, more solid evidence of depressed LV function should be
sought in future studies. Third, we did not explore the electrophys-
iological mechanisms underlying VT/VF, triggered or sustained
by central autonomic inputs. Lastly, as the pretreatment-protocol
was tailored for pathophysiological investigation, implications on
treatment cannot be immediately drawn.
CONCLUSION
Myocardial ETB-receptors modulate autonomic responses during
acute-MI. Their genetic deficiency potentiates the arrhythmo-
genic effects of central sympathetic activation, leading to increased
arrhythmic-mortality. Clonidine induces potent sympatholytic
effects and lowers the incidence of VT/VF, but possibly aggra-
vates heart failure, particularly in the absence of ETB-receptors.
Further research is needed on the central and myocardial inter-
action between ET-1 and sympathetic activation in the setting of
ischemia/infarction.
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